IVIg attenuates complement and improves spinal cord injury outcomes in mice.
about
Disease-modifying effect of intravenous immunoglobulin in an experimental model of epilepsy.Promising neuroprotective strategies for traumatic spinal cord injury with a focus on the differential effects among anatomical levels of injury.MRI in the Study of Animal Models of Neurodegenerative Diseases.Cell cycle and complement inhibitors may be specific for treatment of spinal cord injury in aged and young mice: Transcriptomic analyses.Potential immunotherapies for traumatic brain and spinal cord injury.Elevated Autoantibodies in Subacute Human Spinal Cord Injury Are Naturally Occurring Antibodies
P2860
IVIg attenuates complement and improves spinal cord injury outcomes in mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IVIg attenuates complement and improves spinal cord injury outcomes in mice.
@en
IVIg attenuates complement and improves spinal cord injury outcomes in mice.
@nl
type
label
IVIg attenuates complement and improves spinal cord injury outcomes in mice.
@en
IVIg attenuates complement and improves spinal cord injury outcomes in mice.
@nl
prefLabel
IVIg attenuates complement and improves spinal cord injury outcomes in mice.
@en
IVIg attenuates complement and improves spinal cord injury outcomes in mice.
@nl
P2093
P2860
P50
P356
P1476
IVIg attenuates complement and improves spinal cord injury outcomes in mice
@en
P2093
Jana Vukovic
Milan Basta
Perry F Bartlett
Thiruma V Arumugam
P2860
P304
P356
10.1002/ACN3.318
P577
2016-05-25T00:00:00Z